Table 1.
Eleven microRNAs that were significantly inversely correlated with mRNA gene expression by Partek and DataAssist/TargetScan and down-regulated in t(14;18)–negative FLs without BCL2 expression (FL--) compared with t(14;18)–positive FL (FL+) at a significance level of P < .01
| microRNA | Expressed by B cells | Function | Literature |
|---|---|---|---|
| hsa-miR-138* | Yes (weak) | Down-regulated in non-GC vs GC DLBCL | 9 |
| hsa-miR-139–5p | Yes | Adverse prognostic marker in adenocarcinoma, tumor-associated marker in gastric cancer | 14 |
| hsa-miR-16* | Yes | Inhibits proliferation-associated proteins in CLL | 15,16 |
| hsa-miR-374a | Yes | Tumor-associated marker in colon cancer | 17 |
| hsa-miR-29c* | Yes | Inhibits proliferation-associated and anti–apoptotic proteins in mantle cell lymphoma | 18 |
| hsa-miR-26b* | Yes | Down-regulated in DLBCL compared with FL | 9 |
| hsa-miR-101* | Yes | Inhibits anti–apoptotic proteins in hepatocellular carcinoma | 19 |
| hsa-miR-26a8* | Yes | Cell cycle and MYC inhibitor in lymphoma | 20,15 |
| hsa-miR-485–3p | No | — | — |
| hsa-let-7c* | Yes | Inhibits anti–apoptotic proteins (BCLXL) | 21 |
| hsa-miR-888 | No | — | — |
CLL indicates chronic lymphocytic leukemia; and —, not applicable.
*
Seven of the microRNAs are expressed by B cells and were described to play a role in cell cycle regulation or proliferation or were found to be differentially expressed between GCB DLBCL and ABC DLBCL.